Research programme: immunotherapeutics - BioArctic Neuroscience

Drug Profile

Research programme: immunotherapeutics - BioArctic Neuroscience

Alternative Names: AD-0802; AD-1502; AD-2203; AE-1501; BAN-0805; BAN-2203; BAN-2502; PD-0805

Latest Information Update: 22 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator BioArctic Neuroscience
  • Developer BioArctic
  • Class Monoclonal antibodies; Vaccines
  • Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 20 Sep 2016 BioArctic and AbbVie agree to co-promote and co-develop immunotherapeutics in Parkinson's disease
  • 08 Sep 2010 Preclinical development is ongoing in Sweden for Alzheimer's disease
  • 26 Feb 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top